Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma

Abstract

Three hundred and fifty-three asthmatic patients who remained symptomatic despite treatment with budesonide 800-1200 μg day-1 (or equivalent) were randomized to a new combination therapy comprising salmeterol 50 μg and fluticasone propionate 250 μg (Seretide(TM), Advair(TM), Viani(TM) 50/250 μg) twice daily or budesonide 800 μg twice daily for 24 weeks. Patients kept daily records of their morning and evening peak expiratory flow (PEF), daytime and night-time symptom scores and daytime and night-time use of rescue salbutamol. Mean morning PEF increased by 45 1 min-1 (baseline 361 1 min-1) in the salmeterol/fluticasone propionate combination (SFC) group and by 19 1 min-1 (baseline 358 1 min-1) in the budesonide group over the 24 weeks. The adjusted mean morning PEF over weeks 1 to 24 was significantly greater in the SFC group, despite the > three-fold lower corticosteroid dose (406 vs. 380 1 min-1; P<0·001). A significantly greater improvement in evening PEF was also seen in the SFC group (adjusted mean 416 vs. 398 1 min-1; P<0·001). SFC also provided significantly better control of daytime symptoms and a significantly greater reduction in the requirement for rescue salbutamol compared with budesonide. These results demonstrate that SFC 50/250 μg twice daily is superior to budesonide 800 μg twice daily in the management of patients with moderate to severe asthma who are symptomatic on their existing dose of corticosteroid.